Silence reports 'favorable' outcome of U.S. PTAB decision against Alnylam
Silence Therapeutics reported what it called a "favorable" outcome of a decision by the U.S. Patent Trial & Appeal Board, or PTAB, against Alnylam. In the U.S., Alnylam filed a total of five Post Grant Review petitions against newly-issued Silence patents challenging the validity of the issued claims. In the first decision on Alnylam's petitions, the PTAB denied institution of post-grant review, finding that Alnylam had not met its initial burden of showing that the claims are invalid, Silence stated. "The PTAB's decision not to institute review provides yet another vindication of the strength of Silence's worldwide patent portfolio. Decisions on the remaining petitions are expected over the next several months," the company said.